[1]李柳艳,李建棣,庞玉艳,等.甲状腺乳头状癌组织中E74样ETS转录因子3表达上调的临床意义[J].医学信息,2026,39(10):10-20,31.[doi:10.3969/j.issn.1006-1959.2026.10.002]
　LI Liuyan,LI Jiandi,PANG Yuyan,et al.Clinical Significance of Upregulated Expression of E74-like ETS Transcription Factor 3in Papillary Thyroid Carcinoma Tissue[J].Journal of Medical Information,2026,39(10):10-20,31.[doi:10.3969/j.issn.1006-1959.2026.10.002]
点击复制

甲状腺乳头状癌组织中E74样ETS转录因子3表达上调的临床意义()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年10期
页码:
10-20,31
栏目:
生物信息学
出版日期:
2026-05-15

文章信息/Info

Title:
Clinical Significance of Upregulated Expression of E74-like ETS Transcription Factor 3in Papillary Thyroid Carcinoma Tissue
文章编号:
1006-1959（2026）10-0010-12
作者:
李柳艳; 李建棣; 庞玉艳; 陈 罡; 危丹明
广西医科大学第一附属医院病理科，广西 南宁 530021
Author(s):
LI Liuyan;  LI Jiandi;  PANG Yuyan;  CHEN Gang;  WEI Danming
Department of Pathology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
关键词:
甲状腺乳头状癌; ELF3; 免疫组织化学; RNA-seq; 基因芯片
Keywords:
Papillary thyroid carcinoma;  ELF3;  Immunohistochemistry;  RNA-sequencing;  Gene chip
分类号:
R736.1
DOI:
10.3969/j.issn.1006-1959.2026.10.002
文献标志码:
A
摘要:
目的 分析E74样ETS转录因子3（ELF3）在甲状腺乳头状癌（PTC）中的异常表达及临床意义。方法 收集广西医科大学第一附属医院9例PTC样本，PTC组织作为实验组，对应的癌旁组织作为对照组；从桂林泛谱生物技术有限公司购买4个组织芯片（THC481、THC961、THC1021和THC1501），其中包括45个非癌甲状腺组织和136个PTC组织，采用免疫组化检测ELF3蛋白表达水平。基于GEO、TCGA和GTEx数据库中与PTC相关的基因芯片和RNA-seq数据评估ELF3 mRNA表达，利用cBioPortal数据库查询PTC中ELF3的遗传改变，通过结合ELF3的靶基因、PTC中上调的差异表达基因和ELF3共表达基因，进行富集分析以及蛋白-蛋白相互作用（PPI）分析，探索ELF3在PTC中可能的信号通路和靶基因。结果 免疫组化结果显示，PTC组织（n=145）中ELF3蛋白表达显著高于癌旁组织（n=54）（P＜0.001）。与蛋白质水平一致，与癌旁组织（n=778）相比，PTC组织（n=1136）中的ELF3 mRNA表达上调，标准均数差为0.44（95%CI：0.25~0.62，P=0.019），受试者工作特征曲线下面积为0.68（95%CI：0.64~0.72）。来自cBioPortal的数据表明，6%的PTC病例存在ELF3基因改变。富集分析显示ELF3候选靶基因可能涉及信号转导、细胞黏着、调亡过程等生物学过程，参与构成细胞质膜、膜、细胞溶质等细胞成分，并发挥与蛋白结合等分子功能。此外，观察到ELF3可能与细胞因子-细胞因子相互作用以及MAPK信号通路有关。通过构建PPI网络并结合 ChIP-seq 数据，获得2 个ELF3潜在靶基因，即FN1和ICAM1，且ELF3的表达与FN1和ICAM1呈较强的正相关性。结论 ELF3的上调可能在PTC的发生发展中起重要作用，这些作用可能通过ELF3调控下游靶基因FN1和ICAM1来完成。
Abstract:
Objective To analyze the abnormal expression and clinical significance of E74-like ETS transcription factor 3 (ELF3) in papillary thyroid carcinoma (PTC). Methods Nine PTC samples were collected from the First Affiliated Hospital of Guangxi Medical University. The PTC tissues were used as the experimental group, and the corresponding adjacent tissues were used as the control group. Four tissue chips (THC481, THC961, THC1021 and THC1501) were purchased from Guilin Fanpu Biotech, Inc., including 45 non-cancerous thyroid tissues and 136 PTC tissues. The expression level of ELF3 protein was detected by immunohistochemistry. The expression of ELF3 mRNA was evaluated based on PTC-related gene chips and RNA-seq data in GEO, TCGA and GTEx databases. The cBioPortal database was used to query the genetic changes of ELF3 in PTC. By combining the target genes of ELF3, the up-regulated differentially expressed genes in PTC and the co-expressed genes of ELF3, enrichment analysis and protein-protein interaction (PPI) analysis were performed to explore the possible signaling pathways and target genes of ELF3 in PTC. Results Immunohistochemistry results showed that ELF3 protein expression in PTC tissues (n=145) was significantly higher than that in adjacent non-cancerous tissues (n=54) (P<0.001). Consistent with the protein level, ELF3 mRNA expression was upregulated in PTC tissues (n=1136) compared with adjacent non-cancerous tissues (n=778), with a standardized mean difference of 0.44 (95%CI: 0.25-0.62, P=0.019), and the area under the receiver operating characteristic curve was 0.68 (95%CI: 0.64-0.72). Data from cBioPortal indicated that ELF3 gene alterations were present in 6% of PTC cases. Enrichment analysis revealed that the candidate target genes of ELF3 might be involved in biological processes such as signal transduction, cell adhesion, and apoptotic process, participate in cellular components including plasma membrane, membrane, and cytosol, and exert molecular functions such as protein binding. Furthermore, it was observed that ELF3 might be associated with cytokine-cytokine interactions and the MAPK signaling pathway. By constructing a PPI network combined with ChIP-seq data, two potential target genes of ELF3, namely FN1 and ICAM1,were identified, and the expression of ELF3 showed a strong positive correlation with FN1 and ICAM1. Conclusion The up-regulation of ELF3 may play an important role in the occurrence and development of PTC, which may be achieved by ELF3 regulating downstream target genes FN1 and ICAM1.

参考文献/References:

[1]Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.[2]Boucai L,Zafereo M,Cabanillas ME.Thyroid Cancer: A Review[J].JAMA,2024,331(5):425-435.[3]Xu X,Jing J.Advances on circRNAs Contribute to Carcinogenesis and Progression in Papillary Thyroid Carcinoma[J].Front Endocrinol (Lausanne),2020,11:555243.[4]Jiang HJ,Hsiao PJ.Clinical application of the ultrasound-guided fine needle aspiration for thyroglobulin measurement to diagnose lymph node metastasis from differentiated thyroid carcinoma-literature review[J].Kaohsiung J Med Sci,2020,36(4):236-243.[5]Nakamura T,Nishikawa Y,Shiokawa M,et al.ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway[J].J Pathol,2023,261(1):28-42.[6]Chen L,Huang M,Plummer J,et al.Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma[J].Gut,2020,69(4):630-640.[7]Pan J,Silva TC,Gull N,et al.Lineage-Specific Epigenomic and Genomic Activation of Oncogene HNF4A Promotes Gastrointestinal Adenocarcinomas[J].Cancer Res,2020,80(13):2722-2736.[8]Enfield KSS,Marshall EA,Anderson C,et al.Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma[J].Nat Commun,2019,10(1):5438.[9]Yeung TL,Leung CS,Wong KK,et al.ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells[J].Oncotar[10]Kar A,Gutierrez-Hartmann A.ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2(+) breast cancer patients and is critical for tumorigenesis in HER2(+) breast cancer cells[J].Oncotarget,2017,8(41):69622-69640.[11]Mei S,Qin Q,Wu Q,et al.Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse[J].Nucleic Acids Res,2017,45(D1):D658-D662.[12]Longoni N,Sarti M,Albino D,et al.ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression[J].Cancer Res,2013,73(14):4533-4547.[13]Wang H,Yu Z,Huo S,et al.Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer[J].Int J Biochem Cell Biol,2018,94:98-106.[14]Zheng L,Xu M,Xu J,et al.ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma[J].Cell Death Dis,2018,9(3):387.[15]路彤,李姗,郑鹏生.ELF3在宫颈癌组织中的表达及对HeLa细胞增殖的影响[J].山西医科大学学报,2022,53(8):941-949.[16]He S,Zhang M,Ye Y,et al.GINS2 affects cell proliferation, apoptosis, migration and invasion in thyroid cancer via regulating MAPK signaling pathway[J].Mol Med Rep,2021,23(4):246.[17]Zhang HM,Li ZY,Dai ZT,et al.Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid Cancer[J].Int J Mol Sci,2022,23(19):11989.[18]Chen H,Chen W,Zhang X,et al.E26 transformation (ETS) specific related transcription factor 3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer[J].Oncol Rep,2019,41(1):570-578.[19]Chen C,Ye L,Yi J,et al.FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer[J].Breast Cancer Res Treat,2023,201(3):515-533.[20]贾宁,蹇顺海,赵棋.FN1、PROS1在甲状腺乳头状癌合并桥本甲状腺炎中的表达意义[J].诊断病理学杂志,2024,31(4):313-317.[21]Chen C,Shen Z.FN1 Promotes Thyroid Carcinoma Cell Proliferation and Metastasis by Activating the NF-Κb Pathway[J].Protein Pept Lett,2023,30(1):54-64.[22]Sener BB,Yigit D,Bayra?觭 AT,et al.Inhibition of cell migration and invasion by ICAM-1 binding DNA aptamers[J].Anal Biochem,2021,628:114262.[23]Luo L,Xia L,Zha B,et al.miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells[J].Biomed Pharmacother,2018,106:983-990.

相似文献/References:

[1]郑时玉,郭亚男.c-Met及MACC1在甲状腺乳头状癌中的表达及临床意义[J].医学信息,2022,35(15):36.[doi:10.3969/j.issn.1006-1959.2022.15.007]
　ZHENG Shi-yu,GUO Ya-nan.Expression and Clinical Significance of c-Met and MACC1 in Papillary Thyroid Carcinoma[J].Journal of Medical Information,2022,35(10):36.[doi:10.3969/j.issn.1006-1959.2022.15.007]
[2]李 想,孙春雷,张 懿,等.无充气腋窝入路腔镜手术治疗甲状腺乳头状癌的疗效研究[J].医学信息,2021,34(04):115.[doi:10.3969/j.issn.1006-1959.2021.04.030]
　LI Xiang,SUN Chun-lei,ZHANG Yi,et al.Study on the Curative Effect of Laparoscopic Surgery Non-inflated Axillary Approach in the Treatment of Papillary Thyroid Carcinoma[J].Journal of Medical Information,2021,34(10):115.[doi:10.3969/j.issn.1006-1959.2021.04.030]
[3]刘 彻,艾力·赛丁,苏鹏程.甲状腺乳头状癌颈部淋巴结转移特点及相关危险因素分析[J].医学信息,2019,32(23):70.[doi:10.3969/j.issn.1006-1959.2019.23.019]
　LIU Che,Aili·SaiDing,SU Peng-cheng.Analysis of Cervical Lymph Node Metastasis and Related Risk Factors in Papillary Thyroid Carcinoma[J].Journal of Medical Information,2019,32(10):70.[doi:10.3969/j.issn.1006-1959.2019.23.019]
[4]唐嘉晨,郝玲玲,秦晓茹,等.全腔镜下甲状腺乳头状癌并发症Meta分析[J].医学信息,2021,34(04):78.[doi:10.3969/j.issn.1006-1959.2021.04.021]
　TANG Jia-chen,HAO Ling-ling,QIN Xiao-ru,et al.Meta-analysis of Complications of Papillary Thyroid Carcinoma Under Full Laparoscopic Surgery[J].Journal of Medical Information,2021,34(10):78.[doi:10.3969/j.issn.1006-1959.2021.04.021]
[5]范雪峰,王伦锋,余招焱,等.左侧及右侧中央区淋巴结清扫在甲状腺乳头状癌术中的应用[J].医学信息,2021,34(09):5.[doi:10.3969/j.issn.1006-1959.2021.09.002]
　FAN Xue-feng,WANG Lun-feng,YU Zhao-yan,et al.Left and Right Central Lymph Node Dissection in the Operation of Papillary Thyroid Carcinoma[J].Journal of Medical Information,2021,34(10):5.[doi:10.3969/j.issn.1006-1959.2021.09.002]
[6]徐海燕,潘景润,宫希军,等.CT增强联合甲状腺球蛋白及抗体在甲状腺乳头状癌颈部淋巴结转移中的预测价值[J].医学信息,2021,34(20):119.[doi:10.3969/j.issn.1006-1959.2021.20.030]
　XU Hai-yan,PAN Jing-run,GONG Xi-jun,et al.The Value of CT Enhancement Combined with Thyroglobulin and Antibody in PredictingCervical Lymph Node Metastasis of Papillary Thyroid Carcinoma[J].Journal of Medical Information,2021,34(10):119.[doi:10.3969/j.issn.1006-1959.2021.20.030]
[7]李佳楠,陈春悠.STAT3、NCK1和VEGF在甲状腺乳头状癌中的表达及临床意义[J].医学信息,2022,35(05):94.[doi:10.3969/j.issn.1006-1959.2022.05.023]
　LI Jia-nan,CHEN Chun-you.Expression of STAT3, NCK1 and VEGF in Papillary Thyroid Carcinoma and its Clinical Significance[J].Journal of Medical Information,2022,35(10):94.[doi:10.3969/j.issn.1006-1959.2022.05.023]
[8]李雪松,苏新良,陶冬梅.术前诊断不明确的甲状腺乳头状癌的风险分析[J].医学信息,2024,37(04):119.[doi:10.3969/j.issn.1006-1959.2024.04.021]
　LI Xue-song,SU Xin-liang,TAO Dong-mei.Risk Analysis of Papillary Thyroid Carcinoma with Undefinable Preoperative Diagnosis[J].Journal of Medical Information,2024,37(10):119.[doi:10.3969/j.issn.1006-1959.2024.04.021]
[9]曾恒栋.CT鉴别诊断甲状腺乳头状癌与结节性甲状腺肿的临床价值[J].医学信息,2024,37(22):165.[doi:10.3969/j.issn.1006-1959.2024.22.041]
　ZENG Hengdong.Clinical Value of CT in Differential Diagnosis of Papillary Thyroid Carcinoma and Nodular Goiter[J].Journal of Medical Information,2024,37(10):165.[doi:10.3969/j.issn.1006-1959.2024.22.041]
[10]靳 帅,杨 婷,吴绍平,等.基于SEER数据库的甲状腺乳头状癌患者10年总生存率的预测模型建立及验证[J].医学信息,2025,38(10):75.[doi:10.3969/j.issn.1006-1959.2025.10.013]
　JIN Shuai,YANG Ting,WU Shaoping,et al.Establishment and Validation of a Predictive Model for 10-Year Overall Survival Rate of Patients with Papillary Thyroid Carcinoma Based on the SEER Database[J].Journal of Medical Information,2025,38(10):75.[doi:10.3969/j.issn.1006-1959.2025.10.013]

更新日期/Last Update: 1900-01-01